1.
HIV/AIDS JUNPo e. UNAIDS. Global AIDS Update. Geneva: United Nations.2016.
2.
Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection:
epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci.2012; 16(11):1473-1483.
3.
Firlag-Burkacka E, Swiecki P, Cielniak I, Siwak E, Gizinska J, Bakowska E et al. High
frequency of neurosyphilis in HIV-positive patients diagnosed with early syphilis.
HIV Med.2016; 17(5):323-326.
4.
de Voux A, Kidd S, Grey JA, Rosenberg ES, Gift TL, Weinstock H et al. State-Specific
Rates of Primary and Secondary Syphilis Among Men Who Have Sex with Men - United States,
2015. MMWR Morb Mortal Wkly Rep.2017; 66(13):349-354.
5.
Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M et al. Estimating
the burden of disease attributable to injecting drug use as a risk factor for HIV,
hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013.
Lancet Infect Dis.2016; 16(12):1385-1398.
6.
Kojima N, Klausner JD. An Update on the Global Epidemiology of Syphilis. Curr Epidemiol
Rep.2018; 5(1):24-38.
7.
Al-Mughales JA. Co-infection assessment in HBV, HCV, and HIV patients in Western Saudi
Arabia. J Med Virol.2016; 88(9):1545-1551.
8.
Chung RT. Hepatitis C and B viruses: the new opportunists in HIV infection. Top HIV
Med.2006; 14(2):78-83.
9.
Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in
Asia and Africa. Lancet Infect Dis.2007; 7(6):402-409.
10.
Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T et al. Influence of human immunodeficiency
virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin
Infect Dis.2001; 33(4):562-569.
11.
Thio CL, Smeaton L, Saulynas M, Hwang H, Saravanan S, Kulkarni S et al. Characterization
of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS.2013; 27(2):191-201.
12.
Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management.
Nat Rev Gastroenterol Hepatol.2014; 11(6):362-371.
13.
Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM et al. Rapid
fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS.2007; 21(16):2209-2216.
14.
Sulkowski MS. Management of acute and chronic HCV infection in persons with HIV coinfection.
J Hepatol.2014; 61(1 Suppl):S108-119.
15.
Rockstroh JK. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
Liver Int.2015; 35 Suppl 1:51-55.
16.
de Ledinghen V, Barreiro P, Foucher J, Labarga P, Castera L, Vispo ME et al. Liver
fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative
patients despite antiretroviral therapy. J Viral Hepat.2008; 15(6):427-433.
17.
Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV
co-infection. J Infect Dis.2013; 207 Suppl 1:S26-32.
18.
Palella FJ, Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT et al. Mortality
in the highly active antiretroviral therapy era: changing causes of death and disease
in the HIV outpatient study. J Acquir Immune Defic Syndr.2006; 43(1):27-34.
19.
Liu J, Huang Y, Wang J, Guo N, Li J, Dong X et al. The increasing prevalence of serologic
markers for syphilis among Chinese blood donors in 2008 through 2010 during a syphilis
epidemic. Transfusion.2012; 52(8):1741-1749.
20.
Buchacz K, Patel P, Taylor M, Kerndt PR, Byers RH, Holmberg SD et al. Syphilis increases
HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis
infections. AIDS.2004; 18(15):2075-2079.
21.
Tudor ME, Al Aboud AM: Syphilis. In: StatPearls. edn. Treasure Island FL: StatPearls Publishing LLC.; 2018.
22.
Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of
HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin Liver Dis.2012; 32(2):147-157.
23.
Hu J, Liu K, Luo J. HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development.
Cancer Treat Res.2019; 177:231-250.
24.
Kumar R, Singla V, Kacharya S. Impact and management of hepatitis B and hepatitis
C virus co-infection in HIV patients. Trop Gastroenterol.2008; 29(3):136-147.
25.
Wang LY, Qin QQ, Ge L, Ding ZW, Cai C, Guo W et al. [Characteristics of HIV infections
among over 50-year-olds population in China]. Zhonghua Liu Xing Bing Xue Za Zhi.2016; 37(2):222-226.
26.
Qin M, Qiu-ying Z, Xin-juan Z, Zhen-zhu T, Zhi-yong S. Epidemiological characteristics
of late diagnosed HIV/AIDS cases of 2014 in Guangxi. Chinese Journal of AIDS & STD.2016; 22(4):282-284.
27.
Xie J, Han Y, Qiu Z, Li Y, Li Y, Song X et al. Prevalence of hepatitis B and C viruses
in HIV-positive patients in China: a cross-sectional study. J Int AIDS Soc.2016; 19(1):20659.
28.
Chen JJ, Yu CB, Du WB, Li LJ. Prevalence of hepatitis B and C in HIV-infected patients:
a meta-analysis. Hepatobiliary Pancreat Dis Int.2011; 10(2):122-127.
29.
Fu R, Zhao J, Wu D, Zhang X, Tucker JD, Zhang M et al. A spatiotemporal meta-analysis
of HIV/syphilis epidemic among men who have sex with men living in mainland China.
BMC Infect Dis.2018; 18(1):652.
30.
Wu S, Yan P, Yang T, Wang Z, Yan Y. Epidemiological profile and risk factors of HIV
and HBV/HCV co-infection in Fujian Province, southeastern China. J Med Virol.2017; 89(3):443-449.
31.
Yang T, Chen Q, Li D, Wang T, Gou Y, Wei B et al. High prevalence of syphilis, HBV,
and HCV co-infection, and low rate of effective vaccination against hepatitis B in
HIV-infected patients in West China hospital. J Med Virol.2018; 90(1):101-108.
32.
Chen X, He JM, Ding LS, Zhang GQ, Zou XB, Zheng J. Prevalence of hepatitis B virus
and hepatitis C virus in patients with human immunodeficiency virus infection in Central
China. Arch Virol.2013; 158(9):1889-1894.
33.
Wei Q, Lin H, Ding Y, Liu X, Wu Q, Shen W et al. Liver fibrosis after antiretroviral
therapy in a longitudinal cohort of sexually infected HIV patients in eastern China.
Biosci Trends.2017; 11(3):274-281.
34.
Ding Y, Duan S, Ye R, Yang Y, Yao S, Wang J et al. More improvement than progression
of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected
patients with or without HBV and HCV co-infections. J Viral Hepat.2017; 24(5):412-420.
35.
Jianwei L, Xiaofeng Z, Aiping L, Ying S, Jiangzhu Y, Liang H et al. Analysis of HIV,HBV,HCV
and TP co-infection among patients in Beijing Youan Hospital. CHINESE Journal of AIDS
& STD.2016; 22(8):608-610.
36.
Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection.
Ann Intern Med.1996; 124(7):654-663.
37.
Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent
short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004).
AIDS.2006; 20(18):2371-2379.
38.
Samji H, Yu A, Kuo M, Alavi M, Woods R, Alvarez M et al. Late hepatitis B and C diagnosis
in relation to disease decompensation and hepatocellular carcinoma development. J
Hepatol.2017; 67(5):909-917.
39.
Arando Lasagabaster M, Otero Guerra L. Syphilis. Enferm Infecc Microbiol Clin.2019.
40.
Aebi-Popp K, Wandeler G, Salazar-Vizcaya L, Metzner K, Stockle M, Cavassini M et al.
Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment
of incident HCV infections in HIV-infected men who have sex with men. HIV Med.2018; 19(6):420-425.
41.
Sagnelli E, Sagnelli C, Macera M, Pisaturo M, Coppola N. An update on the treatment
options for HBV/HCV coinfection. Expert Opin Pharmacother.2017; 18(16):1691-1702.
42.
El Sayed A, Barbati ZR, Turner SS, Foster AL, Morey T, Dieterich DT et al. Sofosbuvir
in the treatment of early HCV infection in HIV-infected men. HIV Clin Trials.2017; 18(2):60-66.
43.
de Mendoza C. Hot News: HIV Epidemics - Current Burden and Future Prospects. AIDS
Rev.2017; 19(4):239.
44.
O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R et al. Hepatitis
B virus infection as a neglected tropical disease. PLoS Negl Trop Dis.2017; 11(10):e0005842.
45.
Ning TL, Guo Y, Zheng MN, Bai JY, Zhao X, Zhou N et al. [The characteristics of recent
HIV-1 infection and associated factors in Tianjin]. Zhonghua Yu Fang Yi Xue Za Zhi.2019; 53(3):323-326.
46.
Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV infection and older Americans: the public
health perspective. Am J Public Health.2012; 102(8):1516-1526.
47.
Youssef E, Wright J, Delpech V, Davies K, Brown A, Cooper V et al. Factors associated
with testing for HIV in people aged >/=50 years: a qualitative study. BMC Public Health.2018; 18(1):1204.
48.
Zhang W, Ji Z, Wang L, Xiao D, Yan Y. A meta-analysis of HBsAg-positive rate among
general Chinese populations aged 1--59 years. Infect Dis (Lond).2015; 47(12):878-888.
49.
Liang X, Bi S, Yang W, Wang L, Cui G, Cui F et al. Epidemiological serosurvey of hepatitis
B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine.2009; 27(47):6550-6557.
50.
XU Yi, XIA Xue -qin , ZHANG Shao -bai, LIU Xi -zhen , ZHANG Feng , GUAN Rong-hui
et al. Seroepidemiological study on hepatitis B in Shaanxi Province. Chinese Journal
of Disease Control & Prevention.2010; 14(9):860-862.
51.
He N, Chen L, Lin HJ, Zhang M, Wei J, Yang JH et al. Multiple viral coinfections among
HIV/AIDS patients in China. Biosci Trends.2011; 5(1):1-9.
52.
Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency
virus-infected patients. Semin Liver Dis.2012; 32(2):103-113.
53.
van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis
B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev.2009; 11(3):157-164.
54.
O'Bryan TA, Rini EA, Okulicz J, Messner O, Ganesan A, Lalani T et al. HIV viraemia
during hepatitis B vaccination shortens the duration of protective antibody levels.
HIV Med.2015; 16(3):161-167.
55.
Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M et
al. Long-term response rates of successful hepatitis B vaccination in HIV-infected
patients. Vaccine.2013; 31(7):1040-1044.
56.
Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol
Hepatol.2013; 28 Suppl 1:7-10.
57.
Mijiti P, Yue-xin Z, Wubuli M. Prevalence and risk factors of HIV/HCV co-infection
in HIV/AIDS patients in Xinjiang,China. CHINESE Journal of AIDS & STD.2015; 21(6):477-480.